| Market Capitalization (Millions $) |
343 |
| Shares
Outstanding (Millions) |
79 |
| Employees |
7 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-395 |
| Cash Flow (TTM) (Millions $) |
17 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for central nervous system (CNS) disorders. The company's main objective is to deliver new treatment options to individuals suffering from diseases such as schizophrenia, major depressive disorder, insomnia, and Parkinson's disease.
Through their extensive research and development efforts, Minerva Neurosciences aims to identify and advance novel drug candidates that target the underlying neurobiology of these CNS disorders. They leverage their expertise in preclinical and clinical development, as well as neuropharmacology, to design and execute clinical trials that assess the safety and efficacy of their potential therapies.
Minerva Neurosciences has a diverse pipeline of product candidates, including MIN-101, which is being developed for the treatment of negative symptoms of schizophrenia, and MIN-202, a potential therapy for insomnia disorder. The company also has collaborative research programs with other biopharmaceutical companies and academic institutions to explore additional treatment options for CNS disorders.
As a clinical-stage company, Minerva Neurosciences is focused on advancing their product candidates through various clinical trial phases to ultimately obtain regulatory approvals and bring their therapies to market. They are committed to improving the lives of patients suffering from CNS disorders through the development of innovative and effective treatments.
Company Address: 1500 District Avenue Burlington 1803 MA
Company Phone Number: 600-7373 Stock Exchange / Ticker: NASDAQ NERV
|
